Crown Laboratories and Revance Therapeutics announce $924M Merger
- Aug 14, 2024
- 1 min read
Johnson City and Nashville, TN, August 12, 2024 (PRNewswire) -- Crown Laboratories, Inc. and Revance Therapeutics, Inc. have entered into a merger agreement with Crown offering $6.66 per share in cash for Revance's common stock, valuing the transaction at $924 million. This strategic merger aims to combine the strengths of both companies in the healthcare and skincare industries.
Read full article here.
Comments